Mind Medicine (MindMed) has dosed the first subject in its Phase IIb clinical trial of MM-120 to treat generalised anxiety disorder (GAD), a chronic mental health disorder. 

A total of 200 GAD subjects will be enrolled in the dose-optimisation, multicentre, parallel, double-blind, randomised, placebo-controlled trial of MM-120. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These subjects will be given either a single dose of up to 200µg MM-120 or a placebo. 

The decline in anxiety symptoms four weeks following administration of a single dose of MM-120, compared across the five treatment cohorts, will be the trial’s primary objective.

Evaluating the safety, tolerability, and quality of life, measured up to 12 weeks following dosing, will be the key secondary objectives of the trial.

See Also:

Based on the results from this trial, the dose selection and development strategy for the Phase III clinical trials will be carried out to make a new potential therapy for GAD patients available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MM-120 is a pharmaceutically enhanced form of lysergic acid diethylamide (LSD).

MindMed CEO and director Robert Barrow said: “The initiation of our Phase IIb clinical trial, the largest well-controlled clinical trial of LSD ever conducted, represents a major milestone for MindMed and for the many patients suffering from GAD. 

“This exciting next step in the advancement of LSD builds on the positive topline data presented by our partners at University Hospital Basel in May 2022, which demonstrated the rapid, durable, and statistically significant effects of LSD and its potential to safely mitigate symptoms of anxiety and depression.” 

As per the National Institute of Mental Health (NIMH), the GAD symptoms comprise excessive anxiety and worry that last for more than six months.

These symptoms can cause substantial impairments in social, occupational, and other functioning.